Skip to main content

Table 3 Effects of adding ezetimibe to rosuvastatin or increasing rosuvastatin dosage on lipid and metabolic outcomes

From: Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients

  Values after 12 weeks Change after 12 weeks P Value (Difference Between add on vs. increased dose)
  Ezetimibe add-on group (n = 21) Increased rosuvastatin (n = 18) Ezetimibe add-on group (n = 21) Increased rosuvastatin (n = 18)
ApoB, g/L 0.89 ± 0.25 0.88 ± 0.22 −0.17 ± 0.18* −0.13 ± 0.25* 0.53
ApoA1, g/L 1.47 ± 0.26 1.56 ± 0.30 −0.07 ± 0.25 −0.05 ± 0.24 0.15
ApoB:ApoA1 0.55 ± 0.29 0.60 ± 0.23 −0.15 ± 0.29* −0.12 ± 0.33 0.81
TC, mmol/L 4.23 ± 1.03 4.56 ± 0.75 −1.01 ± 0.79* −0.50 ± 0.63* 0.03
LDL, mmol/L 2.12 ± 0.63 2.07 ± 0.46 −0.68 ± 0.54* −0.48 ± 0.55* 0.37
HDL, mmol/L 1.21 ± 0.27 1.31 ± 0.48 −0.00 ± 0.29 0.03 ± 015 0.72
TC:HDL 3.29 ± 1.41 3.73 ± 0.92 −1.63 ± 2.86* −0.52 ± 0.65* 0.09
TG, mmol/L 1.92 ± 0.98 2.88 ± 1.42 −0.62 ± 0.58* −0.17 ± 0.57 0.03
AIP 0.16 ± 0.30 0.30 ± 0.38 −0.12 ± 0.20* −0.03 ± 0.12 0.13
Non-HDL-C, mmol/L 3.06 ± 0.98 3.25 ± 0.71 −0.97 ± 0.68* −0.53 ± 0.13 0.03
FBG, mmol/L 6.87 ± 2.49 5.82 ± 1.29 0.34 ± 1.28 −0.34 ± 1.75 0.15
hsCRP, mg/L 5.19 ± 7.25 1.72 ± 1.87 −0.60 ± 12.5 −1.06 ± 3.48 0.87
Creatinine, μmol/L 98 ± 58 151 ± 265 8 ± 48 53 ± 258 0.43
ALT, U/L 42 ± 22 34 ± 15 9 ± 17* 1.28 ± 16.6* 0.18
AST, U/L 32 ± 21 29 ± 8 4 ± 14 −0.10 ± 8 0.30
CK, U/L 126 ± 63 189 ± 103 −20 ± 90 12 ± 69 0.23
  1. Data are given as mean (±SD)
  2. *Significant change from their baseline (p < 0.05)
  3. apoB, apolipoprotein B; apoA1,apolipoprotein A1;TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; TG, triglycerides; API, atherogenic index of plasma; FBG, fasting blood glucose; hsCRP, high-sensitivity C-reactive protein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CK, creatine kinase